The Brown Longitudinal Obsessive Compulsive Study: Treatments received and patient impressions of improvement

Journal of Clinical Psychiatry

Volumn 67, Issue 11, 2006, Pages 1713-1720

  Mancebo, Maria C ^a,b   Eisen, Jane L ^b   Pinto, Anthony ^a,b   Greenberg, Benjamin D ^a,b   Dyck, Ingrid R ^a   Rasmussen, Steven A ^b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOTYPAL PERSONALITY DISORDER; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 33845683426     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1107     Document Type: Article

References (53)

1. Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011-1030
2. Greist J, Jefferson J, Kobak K, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
3. Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):1-72
4. Institute of Medicine. Assessing Medical Technologies. Washington, DC: National Academy Press; 1985
5. Tunis S, Stryer D, Clancy C. Practical clinical trials: increasing the value of clinical research for decision making in clinical health policy. JAMA 2003;290:1624-1632
6. Clarke GN. Improving the transition from basic efficacy research to effectiveness studies: methodological issues and procedures. J Consult Clin Psychol 1995;63:718-725
7. Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994;151:441-442
8. Koran LM, Leventhal JL, Fireman B, et al. Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization. Am J Health Syst Pharm 2000;57:1972-1978
9. Denys D, Van Megen HJ, Westenberg HG. The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:109-114
10. Pinto A, Mancebo MC, Eisen JL, et al. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 2006;67:703-711
11. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID/IP, Version 2.0). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1996
12. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1997
13. Rasmussen SA, Eisen J. The epidemiology and clinical features of OCD. In: Jenike MA, ed. Psychiatric Clinics of North America, Vol 15. Philadelphia, Pa: WB Saunders Co; 1992:743-758
14. Steketee G, Perry JC, Goisman RM, et al. The psychosocial treatments interview for anxiety disorders: a method for assessing psychotherapeutic procedures in anxiety disorders. J Psychother Pract Res 1997;6:194-210
15. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale, 1: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
16. Miller IW, Bishop S, Norman WH, et al. The Modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 1985;14:131-142
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:32
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
20. National Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21:714-1124
21. Rufer M, Hand I, Alsleben H, et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 2005;255:121-128
22. Leon AC, Shear MK, Klerman GL, et al. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. J Clin Psychopharmacol 1993;13:327-331
23. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86
24. Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002;63:1004-1009
25. Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64:546-550
26. Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:568-575
27. Statistical Analysis System (SAS) for Windows [computer program]. Version 8. Cary, NC: SAS Institute; 2000
28. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160:1432-1438
29. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-466
30. Vasile RG, Bruce SE, Goisman RM, et al. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 2005;22:59-67
31. Kozak MJ, Coles ME. Treatment for OCD: unleashing the power of exposure. In: Abramowitz JS, Houts AC, eds. Concepts and Controversies in Obsessive-Compulsive Disorder. New York, NY: Springer; 2005:283-304
32. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162:151-161
33. Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive-compulsive disorders: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003;71:394-398
34. Deacon BJ, Abramowitz JS. Patients' perceptions of pharmacological and cognitive-behavioral treatments for anxiety disorders. Behav Ther 2005; 36:139-146
35. Greist JH, Baer L. Psychotherapy for obsessive-compulsive disorder. In: Stein D, Hollander E, eds. Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Publishing; 2002:221-236
36. Kozak MJ, Liebowitz MR, Foa EB. Cognitive behavior therapy and pharmacotherapy for obsessive-compulsive disorder: the NIMH-sponsored collaborative study. In: Goodman WK, Rudorfer MV, Maser JD, eds. Obsessive Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: Lawrence Erlbaum Associates; 2000:501-530
37. Beck JG, Bourg W. Obsessive-compulsive disorder in adults. In: Ammerman RT, Hersen M, eds. Handbook of Behavior Therapy With Children and Adults: A Developmental and Longitudinal Perspective. Boston, Mass: Allyn & Bacon; 1993:167-185
38. Franklin ME. Combining serotonin medication with cognitive-behavior therapy: is it necessary for all OCD patients? In: Abramowitz JS, Houts AC, eds. Concepts and Controversies in Obsessive-Compulsive Disorder. New York, NY: Springer; 2005:377-390
39. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1999;56:121-127
40. Reddy YCJ, D'Souza SM, Shetti C, et al. An 11- to 13-year follow-up of 75 subjects with obsessive-compulsive disorder. J Clin Psychiatry 2005;66:744-749
41. Steketee G, Eisen JL, Dyck I, et al. Predictors of course in obsessive-compulsive disorder. Psychiatry Res 1999;89:229-238
42. Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005;3:23-30
43. Becker MH, Maiman LA, Kirscht JP, et al. The Health Belief Model and prediction of dietary compliance: a field experiment. J Health Soc Behav 1977;18:348-366
44. Gabbard GO, Freedman R. Psychotherapy in the journal: what's missing? Am J Psychiatry 2006;163:182-184
45. Demyttenaere K, Albert A, Mesters P, et al. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry 2005;66:859-863
46. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
47. Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
48. Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;64:1113-1121
49. Dougherty DD, Rauch SL, Jenike MA. Pharmacotherapy for obsessive-compulsive disorder. J Clin Psychol 2004;60:1195-1202
50. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry 1999;60:346-351
51. Hembree EA, Riggs DS, Kozak MJ, et al. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums 2003;8:363-371
52. van Oppen P, van Balkom AJLM, de Haan E, et al. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 2005;66:1415-1422
53. Keuneman RJ, Pokos V, Weerasundera R, et al. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 2005;39:336-343